Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAspirus Arise Adzynma Prior Auth Policy Update | O…
    Ask Trek AI about this page
    CurrentAspirus ArisePolicy Utilization Review Policy 327

    Hematology - Adzynma Utilization Management Medical Policy

    Customize your policy alerts

    Sign up for Aspirus Arise Policy Utilization Review Policy 327 alerts

    Get alerted when Policy Utilization Review Policy 327 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, coverage criteria, dosing, and documentation requirements for Adzynma for treatment of congenital thrombotic thrombocytopenic purpura for Aspirus Medicare Plans.

    Policy Summary
    PayerAspirus Arise
    PolicyHematology - Adzynma Utilization Management Medical Policy
    Policy CodePolicy Utilization Review Policy 327
    Change TypeNo material changes
    Effective Date3/15/2024
    Last ReviewDec 10, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation demonstrating baseline ADAMTS13 activity <10%, absence of anti‑ADAMTS13 antibodies, and pathogenic ADAMTS13 gene variant; approvals are for 1 year when criteria and dosing are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    <10%Required baseline ADAMTS13
    40 IU/kgMax prophylaxis dose
    135 IU/kgMax on-demand weekly
    1 yearInitial approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    All Aspirus Medicare
    Plans governed

    Coverage and Authorization Criteria

    Initial approval — Congenital Thrombotic Thrombocytopenic Purpura

    Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):

    FDA-Approved Indication — diagnostic and prescriber criteria: A) Baseline ADAMTS13 activity <10% (<10 IU/dL); AND B) No anti-ADAMTS13 autoantibodies as determined by diagnostic test; AND C) Presence of a pathogenic variant or mutation in the ADAMTS13 gene (usually homozygous or compound heterozygous); AND D) Medication prescribed by or in consultation with a hematologist.see children nodes

    Documentation for each element is required; baseline refers to pre-treatment values.

    Approved dosing

    Dosing. Approve the following dosing regimens (A and/or B):

    Dosing options: A) Routine prophylaxis: up to 40 IU/kg IV once weekly; OR B) On-demand therapy: up to 135 IU/kg IV per week as needed for acute events (on-demand given daily until 2 days after resolution but total weekly dose not to exceed 135 IU/kg).40 IU/kg weekly; 135 IU/kg weekly max

    On-demand therapy described as daily dosing until 2 days after event resolves; total weekly dose limit applies.

    Coverage of Adzynma is limited to the circumstances explicitly listed in the Recommended Authorization Criteria. Requests for use outside those criteria are not recommended for approval. The criteria will be revised as new published data become available, and providers should anticipate updates that may change covered indications or requirements.

    Diagnostic Thresholds and Coding

    ADAMTS13 activity — threshold
    Threshold valueADAMTS13 activity < 10%
    Equivalent unit< 10 IU/dL
    ContextBaseline (pre-treatment) measurement required for diagnosis and authorization
    DocumentationLaboratory documentation of baseline ADAMTS13 activity required

    Provider Requirements, Documentation, and Exceptions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is recommended. Approval is granted for 1 year when all specified diagnostic and prescribing criteria are met and dosing conforms to the documented regimens. Requests for doses outside the documented dosing will be considered on a case-by-case basis by a clinician (e.g., Medical Director or Pharmacist). Adzynma must be prescribed by or in consultation with a physician who specializes in the condition being treated (hematologist for congenital TTP). Automation: None.

    • Approve for 1 year when ALL FDA‑approved indication criteria are met (ADAMTS13 activity < 10%; no anti‑ADAMTS13 autoantibodies; pathogenic/likely pathogenic ADAMTS13 gene variant; prescribed by/with hematologist).
    • Dosing approvals: routine prophylaxis up to 40 IU/kg IV once weekly; on‑demand therapy up to 135 IU/kg IV per week (total weekly dose not to exceed 135 IU/kg).
    • Requests for doses outside documented dosing considered case‑by‑case by clinician.
    Step Therapy

    Dose Exceptions / Step Therapy

    Clinical Background

    Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare, inherited disorder caused by pathogenic variants in the ADAMTS13 gene that result in severe ADAMTS13 enzyme deficiency (<10% activity). The deficiency leads to microvascular thrombosis with attendant risks of thrombocytopenia, bleeding, stroke, and end-organ damage. Traditional management has relied on plasma-based prophylaxis or on-demand plasma therapy; Adzynma provides recombinant ADAMTS13 replacement for prophylactic or on-demand use.

    Key Definitions

    Congenital TTP (cTTP) — definition
    DefinitionCongenital TTP (cTTP): inherited ADAMTS13 deficiency with activity <10% (<10 IU/dL)
    GeneticsPresence of pathogenic ADAMTS13 gene variant(s), usually homozygous or compound heterozygous
    Autoantibody statusAbsence of anti‑ADAMTS13 autoantibodies required for diagnosis
    Clinical consequenceSevere hereditary deficiency leads to microvascular thrombosis with risk of bleeding, stroke, and organ damage
    Policy Summary
    PayerAspirus Arise
    PolicyHematology - Adzynma Utilization Management Medical Policy
    Policy CodePolicy Utilization Review Policy 327
    Change TypeNo material changes
    Effective Date3/15/2024
    Last ReviewDec 10, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation demonstrating baseline ADAMTS13 activity <10%, absence of anti‑ADAMTS13 antibodies, and pathogenic ADAMTS13 gene variant; approvals are for 1 year when criteria and dosing are met.
    SourceLink
    On This Page
    Coverage and Authorization CriteriaDiagnostic Thresholds and CodingProvider Requirements, Documentation, and ExceptionsClinical BackgroundKey Definitions

    No automated step therapy is specified. Requests that propose a different step or sequencing of therapies than described in this policy will be reviewed individually.

    Documentation Required

    Required Documentation

    Documentation is required as noted in the criteria. Acceptable documentation may include chart notes, laboratory data, diagnostic test results, and genetic test results demonstrating baseline ADAMTS13 activity, absence of anti‑ADAMTS13 autoantibodies, and presence of a pathogenic ADAMTS13 gene variant. Documentation must support the diagnosis and baseline measurements prior to therapy.

    • Baseline ADAMTS13 activity (< 10%) [documentation required].
    • Diagnostic test showing absence of anti‑ADAMTS13 autoantibodies [documentation required].
    • Genetic testing showing pathogenic ADAMTS13 variant [documentation required].
    • Evidence the medication is prescribed by or in consultation with a hematologist.
    Denial Risk

    Denial Trigger

    Requests that do not meet the Recommended Authorization Criteria, or for indications or circumstances not listed in the criteria, are not recommended for approval. Criteria may be updated as new published data become available.

    • Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria.
    • Denial likely if documentation does not demonstrate baseline ADAMTS13 < 10%, absence of anti‑ADAMTS13 autoantibodies, or pathogenic ADAMTS13 gene variant, or if prescribing does not involve a hematologist.